Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$121.15 +4.2%	$107.04	$75.56 ▼ $139.13	$5.80B	0.51	585,898 shs	547,162 shs
CRSP CRISPR Therapeutics	$54.88 +1.4%	$55.23	$30.04 ▼ $71.13	$4.92B	1.8	2.93 million shs	1.28 million shs
NUVL Nuvalent	$74.93 +1.2%	$78.49	$55.53 ▼ $113.51	$5.34B	1.3	437,023 shs	359,402 shs
VERA Vera Therapeutics	$22.54 +5.6%	$22.13	$18.53 ▼ $51.61	$1.36B	1.17	1.65 million shs	1.67 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	-1.86%	+4.66%	+15.35%	+11.86%	+32.19%
CRSP CRISPR Therapeutics	-0.35%	-6.01%	-16.41%	+44.08%	+11.17%
NUVL Nuvalent	-2.67%	-1.28%	-9.04%	+2.46%	-13.21%
VERA Vera Therapeutics	-5.45%	-2.11%	-2.15%	+12.08%	-45.70%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXSM Axsome Therapeutics	4.8214 of 5 stars	4.5	1.0	4.5	4.1	4.2	0.6
CRSP CRISPR Therapeutics	3.6343 of 5 stars	4.3	3.0	0.0	2.2	3.3	0.6
NUVL Nuvalent	3.3674 of 5 stars	4.5	1.0	0.0	3.3	3.3	0.0
VERA Vera Therapeutics	3.7182 of 5 stars	4.5	3.0	0.0	2.4	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	3.07	Buy	$178.00	46.93% Upside
CRSP CRISPR Therapeutics	2.50	Moderate Buy	$71.60	30.47% Upside
NUVL Nuvalent	3.08	Buy	$118.91	58.69% Upside
VERA Vera Therapeutics	2.90	Moderate Buy	$63.00	179.50% Upside

Current Analyst Ratings Breakdown

Latest VERA, NUVL, AXSM, and CRSP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	NUVL Nuvalent	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$112.00
8/7/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$65.00 ➝ $80.00
8/7/2025	VERA Vera Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$56.00 ➝ $53.00
8/6/2025	CRSP CRISPR Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$42.00 ➝ $56.00
8/5/2025	AXSM Axsome Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$173.00 ➝ $176.00
8/5/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$184.00 ➝ $189.00
8/5/2025	CRSP CRISPR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$82.00
8/5/2025	CRSP CRISPR Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$38.00 ➝ $42.00
8/4/2025	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$150.00
8/4/2025	VERA Vera Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Peer Perform
7/22/2025	CRSP CRISPR Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$79.00 ➝ $78.00

(Data available from 8/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$385.69M	15.67	N/A	N/A	$1.18 per share	102.67
CRSP CRISPR Therapeutics	$37.31M	133.78	N/A	N/A	$22.64 per share	2.42
NUVL Nuvalent	N/A	N/A	N/A	N/A	$14.99 per share	N/A
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	$9.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$287.22M	-$5.07	N/A	42.96	N/A	-49.88%	-283.22%	-33.06%	11/11/2025 (Estimated)
CRSP CRISPR Therapeutics	-$366.25M	-$5.43	N/A	N/A	N/A	-1,229.43%	-20.05%	-17.09%	11/4/2025 (Estimated)
NUVL Nuvalent	-$260.76M	-$4.90	N/A	N/A	N/A	N/A	-32.58%	-30.14%	11/11/2025 (Estimated)
VERA Vera Therapeutics	-$152.15M	-$3.58	N/A	N/A	N/A	N/A	-46.70%	-39.46%	11/6/2025 (Estimated)

Latest VERA, NUVL, AXSM, and CRSP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	NUVL Nuvalent	-$1.27	-$1.31	-$0.04	-$1.39	N/A	N/A
8/5/2025	Q2 2025	VERA Vera Therapeutics	-$0.82	-$1.20	-$0.38	-$1.20	N/A	N/A
8/4/2025	Q2 2025	AXSM Axsome Therapeutics	-$1.00	-$0.92	+$0.08	-$0.97	$140.02 million	$150.04 million
8/4/2025	Q2 2025	CRSP CRISPR Therapeutics	-$1.47	-$1.29	+$0.18	-$2.40	$6.44 million	$0.89 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	1.66	1.57	1.51
CRSP CRISPR Therapeutics	N/A	16.61	16.61
NUVL Nuvalent	N/A	13.57	13.57
VERA Vera Therapeutics	0.16	17.03	17.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
CRSP CRISPR Therapeutics	69.20%
NUVL Nuvalent	97.26%
VERA Vera Therapeutics	99.21%

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	22.40%
CRSP CRISPR Therapeutics	4.10%
NUVL Nuvalent	10.20%
VERA Vera Therapeutics	16.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	49.90 million	38.72 million	Optionable
CRSP CRISPR Therapeutics	460	90.95 million	87.22 million	Optionable
NUVL Nuvalent	40	72.11 million	64.75 million	Optionable
VERA Vera Therapeutics	40	63.82 million	53.42 million	Optionable

VERA, NUVL, AXSM, and CRSP Headlines

Recent News About These Companies

Vera Therapeutics to Participate at Upcoming Investor Conferences

August 26 at 4:05 PM | globenewswire.com

Vera Therapeutics, Inc. $VERA Shares Bought by T. Rowe Price Investment Management Inc.

August 26 at 4:49 AM | marketbeat.com

Russell Investments Group Ltd. Purchases 127,646 Shares of Vera Therapeutics, Inc. $VERA

August 26 at 3:42 AM | marketbeat.com

Rusfertide Earns Breakthrough Therapy Designation in Polycythemia Vera

August 26 at 3:38 AM | curetoday.comC

Vanguard Group Inc. Cuts Stock Position in Vera Therapeutics, Inc. $VERA

August 26 at 3:05 AM | marketbeat.com

Vera Therapeutics: Institutional Confidence Meets Analytical Skepticism

August 25 at 12:36 PM | aktiencheck.deA

Vera Therapeutics, Inc. $VERA Stake Boosted by Algert Global LLC

August 24 at 4:50 AM | marketbeat.com

19,597 Shares in Vera Therapeutics, Inc. $VERA Acquired by Fox Run Management L.L.C.

August 21, 2025 | marketbeat.com

Lord Abbett & CO. LLC Has $3.57 Million Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)

August 19, 2025 | marketbeat.com

Can Vera Therapeutics’ (VERA) Widening Losses Challenge Its Path to Sustainable Growth?

August 19, 2025 | finance.yahoo.com

Deutsche Bank AG Purchases 82,483 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

August 15, 2025 | marketbeat.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Recommendation of "Moderate Buy" by Analysts

August 10, 2025 | marketbeat.com

FY2025 EPS Estimates for VERA Cut by Cantor Fitzgerald

August 9, 2025 | marketbeat.com

HC Wainwright Has Negative Estimate for VERA Q3 Earnings

August 9, 2025 | marketbeat.com

What is Lifesci Capital's Forecast for VERA Q3 Earnings?

August 9, 2025 | marketbeat.com

JPMorgan Chase & Co. Issues Pessimistic Forecast for Vera Therapeutics (NASDAQ:VERA) Stock Price

August 8, 2025 | marketbeat.com

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 8, 2025 | globenewswire.com

Vera Therapeutics Signs New Sales Agreement with TD Securities

August 8, 2025 | theglobeandmail.com

Q3 Earnings Forecast for Vera Therapeutics Issued By Wedbush

August 8, 2025 | marketbeat.com

Vera Therapeutics (VERA) to Release Quarterly Earnings on Thursday

August 7, 2025 | marketbeat.com

Vera Therapeutics (NASDAQ:VERA) Posts Earnings Results, Misses Estimates By $0.38 EPS

August 6, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VERA, NUVL, AXSM, and CRSP Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$121.15 +4.84 (+4.16%)

Closing price 04:00 PM Eastern

Extended Trading

$121.15 0.00 (0.00%)

As of 07:57 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

CRISPR Therapeutics NASDAQ:CRSP

$54.88 +0.75 (+1.39%)

Closing price 04:00 PM Eastern

Extended Trading

$54.90 +0.02 (+0.04%)

As of 07:59 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Nuvalent NASDAQ:NUVL

$74.93 +0.88 (+1.19%)

Closing price 04:00 PM Eastern

Extended Trading

$74.95 +0.02 (+0.03%)

As of 04:34 PM Eastern

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Vera Therapeutics NASDAQ:VERA

$22.54 +1.20 (+5.62%)

Closing price 04:00 PM Eastern

Extended Trading

$22.55 +0.01 (+0.04%)

As of 06:09 PM Eastern

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time